Citi Neuro Centre Private Limited

Citi Neuro Centre Private Limited - healthcare in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U74900TG2014PTC096132 Incorporated 28 October 2014 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Private Limited Company healthcare
Revenue · FY 2025
₹44,776
▲ 15% YoY
Net loss · FY 2025
₹8.24 Lakh
Latest filing
EBITDA · FY 2025
₹44,551
EBITDA margin 99.5%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹4.95 Cr
Issued & subscribed
Company age
12 yrs
Est. 2014
Directors on board
3
As per MCA filings
Brands
1
Associated brands

About Citi Neuro Centre Private Limited

Data last updated:

Citi Neuro Centre Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the hospital and clinical services segment of the healthcare sector. It was incorporated on 28 October 2014 and has been in existence for over 12 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U74900TG2014PTC096132.

The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.95 Cr. It is led by directors including Sreenivas Pyata and Ala Reddy Venkateshwer.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H.No.8 – 2 – 293/82/A/443 Jubilee Hills Hyderabad, Telangana, India – 500034.

As per the financials filed for FY 2025, the company reported a revenue of ₹44,776, a growth of 15% compared to the previous year. For the same year it recorded a net loss of ₹8.24 Lakh and EBITDA of ₹44,551 (EBITDA margin 99.5%). Revenue has declined at a compounded annual rate (CAGR) of 85% over five years.

The company is associated with 1 brand: Citi Neuro Centre. The company has 4 deals on record (3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹6.08 Cr; the latest was in February 2018.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website citineurocentre.com.

Company details

CIN U74900TG2014PTC096132
Registration Number 096132
Incorporation Date 28 October 2014
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant

Contact details

Citi Neuro Centre Private Limited's registered office is in Hyderabad, Telangana. Its website is citineurocentre.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    H.No.8 – 2 – 293/82/A/443 Jubilee Hills Hyderabad, Telangana, India – 500034
  • Industry
    Healthcare, Hospitals

To see the full contact details of Citi Neuro Centre Private Limited, buy the company report.

Comprehensive company report
Citi Neuro Centre Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Citi Neuro Centre operates one associated brand: Citi Neuro Centre. Each brand links to its own profile.

BrandDescriptionWebsite
Offers neurology, neurosurgery, and medical services across multiple branches.citineurocentre.com

Financials of Citi Neuro Centre Private Limited

FY 2025 filings available

Citi Neuro Centre Private Limited reported revenue of ₹44,776 (up 15% YoY) for FY 2025.

Revenue · FY 2025
₹44,776 ▲ 15%
Net loss · FY 2025
₹8.24 Lakh
EBITDA · FY 2025
₹44,551 margin 99.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 15%
5 years · compounded
▼ 85%
EBITDA CAGR growth
1 year
▲ 14%
3 years · compounded
▲ 381%
5 years · compounded
▼ 80%

Revenue rose 15% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 85%. EBITDA rose 14% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹44,551
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹8.24 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin99.5%
Net Profit Margin
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Citi Neuro Centre Private Limited, buy the company report.

Board of directors of Citi Neuro Centre Private Limited

Citi Neuro Centre has 3 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sreenivas PyataDirector15 Sep 201511 Years 1 MonthsCurrent
Ala Reddy VenkateshwerDirector15 Sep 201511 Years 1 MonthsCurrent
Arradi VamshidharDirector28 Oct 201412 Years 0 MonthsCurrent

Auditor

Citi Neuro Centre Private Limited is audited by VNK & Associates for the financial year 2022.

Auditor firmFinancial yearFirm registration number
VNK & AssociatesFY 2022015492S

Shareholding

The shareholding of Citi Neuro Centre Private Limited is on record for 5 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2021FY 2020FY 2019FY 2018FY 2017
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Citi Neuro Centre Private Limited, buy the company report.

Deals & funding

Citi Neuro Centre Private Limited has 4 deals on record (3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹6.08 Cr; the latest was in February 2018.

Total deals
4
Funding rounds
3
Secondary share transfer
1
Disclosed funding
₹6.08 Cr

Deals on record (4 of 4)

WhenDealAmountParties
Feb 2018Funding round₹1.75 CrInvestors: 3 individuals
May 2016Funding round₹2.6 CrInvestors: 4 individuals
Feb 2016Funding round₹1.73 CrInvestors: 3 individuals
Mar 2015Secondary share transferUndisclosedBuyer: 4 individuals
Seller: 3 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Citi Neuro Centre Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

No GST registration is on our record for Citi Neuro Centre Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Citi Neuro Centre Private Limited has 12 board changes on record since 2014: 3 appointments and 9 cessations. The latest: Buchipudi Reddy Sambasiva ceased to be Director on 22 Feb 2021.

AGM
Citi Neuro Centre Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Citi Neuro Centre Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Buchipudi Reddy Sambasiva ceased to be Director.
Ceased
Bhargava Prasad Cheerla ceased to be Director.
Ceased
Chakrala Kishore Rathna ceased to be Director.
Ceased
Chandrasekar Reddy Bhumireddy ceased to be Director.
Ceased
Ravi Varma Dandu ceased to be Director.
Ceased
Vamseemohan Beeram ceased to be Director.
Ceased
Sridhar Peddireddy ceased to be Director.
Ceased
Ala Reddy Venkateshwer ceased to be Additional Director.
Ceased
Sreenivas Pyata ceased to be Additional Director.
Appointed
Ala Reddy Venkateshwer was appointed as Director.

3 earlier events are in the company report.

Frequently asked questions

Citi Neuro Centre is an active private limited company based in Hyderabad, Telangana, India. The company works in hospitals, within the healthcare industry. It was incorporated on 28 October 2014 (12+ years old) and is registered under CIN U74900TG2014PTC096132.

Citi Neuro Centre has 3 current directors:

The latest financial statements of Citi Neuro Centre on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Citi Neuro Centre is U74900TG2014PTC096132. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Citi Neuro Centre was incorporated on 28 October 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.

Citi Neuro Centre has 4 deals on record (3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹6.08 Cr; the latest was in February 2018.

Buchipudi Reddy Sambasiva ceased to be Director on 22 Feb 2021. Bhargava Prasad Cheerla ceased to be Director on 04 Jan 2021. Chakrala Kishore Rathna ceased to be Director on 04 Jan 2021. Citi Neuro Centre has 12 board changes on record in total.

Citi Neuro Centre can be reached through the website citineurocentre.com. Its registered office is in Hyderabad, Telangana, India.

The registered office of Citi Neuro Centre is at H.No.8 – 2 – 29382A443 Jubilee Hills Hyderabad, Telangana, India – 500034.

Citi Neuro Centre operates in the healthcare industry, in the hospitals segment.